AORT ARTIVION, INC.
Surgical & Medical Instruments & Apparatus · NYSE · SEC CIK 784199 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY14.0%
TTM net income YoY-92.5%
TTM EPS YoY-56.5%
Revenue 3-yr CAGR12.4%
Net income 3-yr CAGR—
Margins
Gross margin63.3%
Operating margin2.3%
Net margin-3.7%
FCF margin-9.2%
EBITDA margin7.7%
Returns
ROE-4.0%
ROA-1.9%
ROIC (approx.)1.3%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets57.2%
Debt / equity0.81x
Current ratio4.42x
Interest coverage0.41x
Cash quality & payout
Operating cash flow / net income-0.85x
Accruals ratio-3.4%
Payout ratio—
Capex / revenue12.3%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $441.33M | $388.54M | $354.00M | $313.79M | $298.84M |
| Cost of revenue | $157.10M | $139.76M | $124.83M | $111.27M | $101.32M |
| Gross profit | $284.23M | $248.78M | $229.18M | $202.52M | $197.51M |
| R&D expense | $30.99M | $28.45M | $28.71M | $38.88M | $35.55M |
| SG&A expense | $226.49M | $181.46M | $208.98M | $157.44M | $169.77M |
| Operating income | $33.74M | $38.87M | $5.74M | $6.20M | $8.12M |
| Interest expense | $26.58M | $34.28M | $25.30M | $18.22M | $16.89M |
| Pretax income | $14.78M | -$7.51M | -$21.59M | -$14.98M | -$14.83M |
| Income tax | $5.01M | $5.84M | $9.10M | $4.21M | $7,000 |
| Net income | $9.77M | -$13.36M | -$30.69M | -$19.19M | -$14.83M |
| EBITDA | $56.20M | $63.08M | $28.82M | $28.64M | $32.09M |
| EPS (basic) | 0.22 | -0.32 | -0.75 | -0.48 | -0.38 |
| EPS (diluted) | 0.21 | -0.32 | -0.75 | -0.48 | -0.38 |
| Weighted avg. shares (diluted) | 47.16M | 41.68M | 40.74M | 40.03M | 38.98M |
| Balance sheet | |||||
| Cash & equivalents | $64.91M | $53.46M | $58.94M | $39.35M | $55.01M |
| Receivables | $89.76M | $79.46M | $71.80M | $61.82M | $53.02M |
| Inventory | $92.43M | $79.77M | $81.98M | $74.48M | $76.97M |
| Current assets | $358.08M | $290.08M | $280.67M | $247.33M | $247.70M |
| PP&E, net | $64.99M | $36.40M | $38.36M | $38.67M | $37.52M |
| Goodwill | $254.09M | $240.96M | $247.34M | $243.63M | $250.00M |
| Intangibles | $123.66M | $128.05M | $142.59M | $151.26M | $166.99M |
| Total assets | $884.80M | $789.10M | $792.40M | $762.80M | $793.05M |
| Current liabilities | $101.56M | $66.82M | $57.86M | $49.67M | $44.95M |
| Short-term debt | $0 | $195,000 | $1.45M | $1.61M | $1.63M |
| Long-term debt | $215.11M | $314.15M | $305.53M | $306.50M | $307.49M |
| Total debt | $215.11M | $314.35M | $306.98M | $308.11M | $309.12M |
| Total liabilities | $436.56M | $512.90M | $510.62M | $478.47M | $492.32M |
| Shareholders' equity | $448.23M | $276.20M | $281.78M | $284.33M | $300.73M |
| Net debt | $150.21M | $260.88M | $248.04M | $268.76M | $254.11M |
| Shares outstanding | — | — | — | 41.83M | — |
| Cash flow statement | |||||
| Operating cash flow | $39.88M | $22.24M | $18.82M | -$5.15M | -$2.58M |
| Capital expenditure | $39.04M | $11.19M | $9.75M | $10.71M | $13.09M |
| Free cash flow | $839,000 | $11.05M | $9.07M | -$15.87M | -$15.68M |
| Investing cash flow | -$42.04M | -$28.19M | -$502,000 | -$10.71M | $5.66M |
| Financing cash flow | $11.28M | $2.20M | $865,000 | -$1.64M | -$12.22M |
| Depreciation & amortization | $22.46M | $24.20M | $23.08M | $22.44M | $23.98M |
| Stock-based compensation | $24.39M | $14.24M | $14.42M | $12.34M | $10.71M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.